Back to Stocks

STOK

Stoke Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Stoke Therapeutics has successfully transitioned into a late-stage clinical entity, anchored by a robust balance sheet and a high-conviction lead asset.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline liquidity, a deeper analysis of Stoke's cash flow reveals a precarious burn rate. The company reported a net loss of $50 million and a cash outflow from operations of $60.6 million in the first quarter of 2026.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every STOK filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing paints a picture of a company in a race against time. Stoke has successfully stockpiled capital to reach its primary clinical catalyst, but the cost of maintaining that infrastructure is high. The shift in revenue from $158.6 million to $6.2 million reflects the transition from recognizing upfront partnership fees to the steady-state costs of late-stage development. The core tension for investors is whether the projected 2028 runway is realistic given the accelerating R&D and SG&A spend. Ultimately, Stoke is a high-beta play on the SCN1A target. The ability to maintain the current cash position while executing the EMPEROR trial is the immediate operational goal, but the long-term thesis depends entirely on the mid-2027 data. If successful, the Biogen partnership and the $411 million cushion provide a professional launchpad; if unsuccessful, the company lacks a diversified revenue stream to pivot effectively.

Selected Quarter

Core Takeaway

Stoke has shifted from a research lab to a late-stage clinical company with sufficient cash to reach its next major catalyst, but operating losses remain high.

Investor Lens

The trade-off is between the high potential of a first-in-class Dravet treatment and the risk of a total loss if the binary Phase 3 trial fails.

Watch Next

Final patient randomization for the EMPEROR trial in June 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.03Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Operating expenses increased to $59.6 million as the company scales for commercial readiness.

margin compression
70%
bullishMay 7

Successfully raised $168.5 million through controlled equity offerings in early 2026.

capital raise
60%
neutralMay 7

Revenue dropped sharply due to the timing of one-time milestone payments from partners.

earnings miss
40%
bearishMay 7

Operating expenses increased to $59.6 million as the company scales for commercial readiness.

margin compression
70%
bullishMay 7

Successfully raised $168.5 million through controlled equity offerings in early 2026.

capital raise
60%
neutralMay 7

Revenue dropped sharply due to the timing of one-time milestone payments from partners.

earnings miss
40%
bearishMay 7

Operating expenses increased to $59.6 million as the company scales for commercial readiness.

margin compression
70%
bullishMay 7

Successfully raised $168.5 million through controlled equity offerings in early 2026.

capital raise
60%
neutralMay 7

Revenue dropped sharply due to the timing of one-time milestone payments from partners.

earnings miss
40%
bearishMay 7

Operating expenses increased to $59.6 million as the company scales for commercial readiness.

margin compression
70%
bullishMay 7

Successfully raised $168.5 million through controlled equity offerings in early 2026.

capital raise
60%
neutralMay 7

Revenue dropped sharply due to the timing of one-time milestone payments from partners.

earnings miss
40%
bearishMay 7

Operating expenses increased to $59.6 million as the company scales for commercial readiness.

margin compression
70%
bullishMay 7

Successfully raised $168.5 million through controlled equity offerings in early 2026.

capital raise
60%
neutralMay 7

Revenue dropped sharply due to the timing of one-time milestone payments from partners.

earnings miss
40%
bearishMay 7

Operating expenses increased to $59.6 million as the company scales for commercial readiness.

margin compression
70%
bullishMay 7

Successfully raised $168.5 million through controlled equity offerings in early 2026.

capital raise
60%
neutralMay 7

Revenue dropped sharply due to the timing of one-time milestone payments from partners.

earnings miss
40%
bearishMay 7

Operating expenses increased to $59.6 million as the company scales for commercial readiness.

margin compression
70%
bullishMay 7

Successfully raised $168.5 million through controlled equity offerings in early 2026.

capital raise
60%
neutralMay 7

Revenue dropped sharply due to the timing of one-time milestone payments from partners.

earnings miss
40%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing paints a picture of a company in a race against time. Stoke has successfully stockpiled capital to reach its primary clinical catalyst, but the cost of maintaining that infrastructure is high. The shift in revenue from $158.6 million to $6.2 million reflects the transition from recognizing upfront partnership fees to the steady-state costs of late-stage development. The core tension for investors is whether the projected 2028 runway is realistic given the accelerating R&D and SG&A spend. Ultimately, Stoke is a high-beta play on the SCN1A target. The ability to maintain the current cash position while executing the EMPEROR trial is the immediate operational goal, but the long-term thesis depends entirely on the mid-2027 data. If successful, the Biogen partnership and the $411 million cushion provide a professional launchpad; if unsuccessful, the company lacks a diversified revenue stream to pivot effectively.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.